Advertisements



Alnylam may open lower on narrower label than hoped, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 10th, 2018

Regeneron asthma label for Dupixent broad as hoped, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallOct 22nd, 2018

Broadcom will likely have to lower full-year guidance, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewall9 hr. 33 min. ago

Piper says BioCryst magnitude of attack reduction in HAE lower than hoped for

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 21st, 2019

Akebia shares should be bought at the open, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 10th, 2019

Alnylam shares reacting to increased expense guidance, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMay 1st, 2019

Alnylam Initiates Phase III ILLUMINATE-B Study on Lumasiran

Alnylam (ALNY) initiates phase III study on lumasiran and also reports new positive efficacy results from the ongoing phase II open-label extension (OLE) study on.....»»

Category: personnelSource: nytApr 16th, 2019

Lumasiran could give Alnylam 3 RNAi drugs approved by 2021, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2019

Alnylam alliance with Regeneron a "clear positive," says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 8th, 2019

Myriad traded lower on "minor" United Healthcare change, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 1st, 2019

Gilead HIV drugs" price increase 30% lower than prior years, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 17th, 2019

Alnylam (ALNY) Reports Positive Data for RNAi Candidate

Alnylam (ALNY) announced encouraging results from phase I and phase I/II open-label extension studies of givosiran, which is being evaluated for the treatment of a.....»»

Category: worldSource: nytApr 17th, 2018

Piper Jaffray confident in Alnylam Givosiran approval

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 15th, 2018

Alnylam price target cut to $160 from $182 at Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJun 27th, 2018

Ionis approval narrower than expected, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 11th, 2018

Piper Jaffray sees earlier EU approval of Alnylam"s patisiran after CHMP nod

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallJul 27th, 2018

Piper Jaffray, JPMorgan Are "Logging Out" Of LogMeIn

LogMeIn Inc (NASDAQ: LOGM), a provider of cloud-based connectivity, reported second-quarter results Thursday that prompted a sell-off in the stock and lower ratings from multiple Street analysts Latest .....»»

Category: blogSource: benzingaJul 27th, 2018

Alnylam should be bought on post-approval weakness, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 13th, 2018

Piper Jaffray "surprised" Array BioPharma shares are trading lower post-results

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 14th, 2018

Regeneron"s fasinumab safety remains "open question," says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 16th, 2018

Pfizer data leave room for Alnylam to compete, says Piper Jaffray

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallAug 27th, 2018